Study Reports on Safety, Efficacy of Bevacizumab Biosimilar Stivant®

Published: August 19, 2021

A research study including 351 patients (385 eyes) at Farabi Eye Hospital, Tehran, Iran, September 2018 to February 2019, studied the use of the intravitreal injection of the bevacizumab biosimilar Stivant®. The study reported the relative safety of Stivant® and also its efficacy in consistent improvement of Central Macular Thickness in patients and an improved Best Corrected Visual Acuity in a portion of patients.(1)

The study included 234 eyes with Diabetic Macular Edema, 87 eyes with Age-Related Macular Degeneration, and 64 eyes with Macular Edema secondary to Retinal Vein Occlusion. The biosimilar was injected in the eyes in three consecutive months and changes in Central Macular Thickness and Best Corrected Visual Acuity were measured at baseline and monthly including one month after the third injection. “Our limited experience showed that the intravitreal injection of Stivant® was well tolerated,” the researchers stated in their conclusion. The researchers called for a randomized clinical trial to evaluate the efficacy of Stivant® compared with bevacizumab.(1)

 


 

(1) Mirshahi, A. M.D., Lashay, A. M.D., et. al., Journal of Ophthalmic and Vision Research, Intraocular Injection of Stivant® (A Biosimilar to Bevacizumab): A Case Study, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7841280/